Multicomponent Antiviral Composition for SARS-CoV-2 Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of established prophylactic strategies and direct antiviral treatments for preventing and treating SARS-CoV-2 infections and the associated COVID-19 symptoms, with existing treatments having limited effectiveness and potential side effects.
Innovation Solution
A pharmaceutical composition comprising lactoferrin, S1RA, entecavir, lomitapide, metoclopramide, bosutinib, thioguanine, Z-FA-FMK, amiodarone, verapamil, gilteritinib, clofazimine, niclosamide, and remdesivir is administered to inhibit viral entry, replication, and modulate host cell responses, potentially combined with remdesivir or hydroxychloroquine, to treat and prevent SARS-CoV-2 infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If remdesivir is used to treat SARS-CoV-2 infection, then antiviral efficacy is improved, but safety profile and side effects worsen
Solution Approach 1:
The patent combines remdesivir with lactoferrin and other agents in a multi-component pharmaceutical composition. This combination approach allows the synergistic effect where lactoferrin enhances the antiviral activity of remdesivir while potentially mitigating its side effects, thereby improving the safety profile without compromising efficacy
Solution Approach 2:
The invention uses a composite pharmaceutical composition containing multiple substances (remdesivir, lactoferrin, S1RA, entecavir, lomitapide, metoclopramide, bosutinib, thioguanine, fedratinib, Z-FA-FMK, amiodarone, verapamil, gilteritinib, clofazimine, niclosamide). This composite formulation leverages the complementary mechanisms of action of different drugs to achieve enhanced antiviral effect with improved safety profile
2Reliability
If hydroxychloroquine is used to treat SARS-CoV-2 infection, then antiviral activity is improved, but safety profile and side effects worsen
Solution Approach 1:
The patent combines hydroxychloroquine with lactoferrin and other agents in a multi-component pharmaceutical composition. This combination approach allows the synergistic effect where lactoferrin enhances the antiviral activity of hydroxychloroquine while potentially mitigating its side effects, thereby improving the safety profile without compromising efficacy
Solution Approach 2:
The invention uses a composite pharmaceutical composition containing multiple substances (hydroxychloroquine, lactoferrin, S1RA, entecavir, lomitapide, metoclopramide, bosutinib, thioguanine, fedratinib, Z-FA-FMK, amiodarone, verapamil, gilteritinib, clofazimine, niclosamide). This composite formulation leverages the complementary mechanisms of action of different drugs to achieve enhanced antiviral effect with improved safety profile
3Reliability
If multiple antiviral drugs are combined to enhance efficacy, then antiviral effect is improved, but device complexity and formulation complexity worsen
Solution Approach 1:
The patent creates a universal pharmaceutical composition that can be used for multiple purposes: treating active SARS-CoV-2 infection, preventing infection, and managing COVID-19 symptoms. The formulation includes a core group of antiviral agents (remdesivir, hydroxychloroquine, lactoferrin) that provide broad-spectrum antiviral activity, along with additional agents (S1RA, entecavir, lomitapide, metoclopramide, bosutinib, thioguanine, fedratinib, Z-FA-FMK, amiodarone, verapamil, gilteritinib, clofazimine, niclosamide) that target specific viral mechanisms and host responses, making the formulation multi-functional and adaptable to different patient needs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively suppresses pro-inflammatory cytokine activity, enhances NK and neutrophil activity, and inhibits viral entry, demonstrating antiviral efficacy and safety in preclinical trials, with lactoferrin potentiating the effects of remdesivir and hydroxychloroquine, offering a promising therapeutic adjunct for COVID-19.
Implementation Method 1
lactoferrin inhibits viral entry and replication
Implementation Method 2
lactoferrin inhibits viral entry and replication
Implementation Method 3
The composition effectively suppresses pro-inflammatory cytokine activity
Implementation Method 4
enhances NK and neutrophil activity
Implementation Method 5
lactoferrin potentiating the effects of remdesivir and hydroxychloroquine
Data Source
AI summary
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical compositions capable of preventing, treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 vims (e.g., COVID-19). The invention further relates to methods of preventing, treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 vims (e.g., COVID-19), comprising administering to a subject (e.g., a human patient) a pharmaceutical composition comprising lactoferrin, S1RA, entecavir, lomitapide, metoclopramide, bosutinib, thioguanine, fedratinib, Z-FA-FMK, amiodarone, verapamil, gilteritinib, clofazimine, niclosamide, and remdesivir (alone or with additional agents).